Dr Sheila M Worlledge, Dr M C Brain, Dr A C Cooper, Dr J R Hobbs and Professor J V Dacie (Royal Postgraduate Medical School, London) Immunosuppressive Drugs in the Treatment of Autoimmune Haemolytic Anaemia Because it is clear that auto-antibodies against red cells play a major part in causing the anmmia of autoimmune hkmolytic anmmia (AIHA) it seems logical to try to control the anemia by using drugs which are known to be effective in controlling the growth of antibody-forming cells. What, of course, is needed is a drug that selectively destroys the cells producing the abnormal antibody without affecting the other active cells. In practice one has to use a drug which is toxic to all active cells to some extent. A preliminary report of our experience of the effectiveness of these drugs in AIHA is given here.
Chronic Cold Hatmagglutinin Disease
In chronic cold hemagglutinin disease (CHAD) the abnormal antibody is a monoclonal IgM immunoglobulin often present in the plasma in large amounts. By analogy with Waldenstrom's macroglobulintmia this antibody should be produced by lymphocyte-like cells even though experiments with fluorescein-tagged anti-IgM have given positive results only with plasma cells (Curtain & Baumgarten 1965) . Chlorambucil and cyclophosphamide seem to be the most useful drugs in the treatment of chronic lymphatic leukw,mia. Chlorambucil has also been shown to be effective in the treatment of Waldenstrom's macroglobulinamia (Bayrd 1961) and it was because of this that Olesen first used this drug to treat chronic CHAD in 1964 (Olesen 1964) .
Results of treatment with chlorambucil: Table 1 summarizes the results of treatment with chlorambucil in 9 patients. In 3 patients there has been good response as judged by a rise in hemoglobin level and a fall in the abnormal antibody titre and IgM level. One patient, Case 4, showed temporary improvement, but later became resistant to this drug and finally died of a generalized reticulosarcoma. Two patients, who have been treated for 12 and 9 months respectively, have shown some improvement as judged by a fall in IgM levels. Three patients, treated for 4, 8 and 14 months respectively, have shown no response at all. The dose of chlorambucil has usually been small and most patients have been treated with either 2 or 4 mg a day. The main side-effects were transient falls in white cells, platelets or reticulocytes, which all responded readily to stopping the drug or reducing the dose. In one patient who showed no improvement and who was treated for only 4 months the drug had to be stopped because of vertigo.
Figs 1 and 2 show the hematology charts of two of these patients, Case 3 (J M) and Case 4 (W S). Their case histories are summarized below.
Case 3 J M, man aged 52 Chronic CHAD was diagnosed in 1962. He had kept a chart of his hamoglobin level over the years and the overall result shows a steady downward trend. He was first seen by us in September 1966 when he had evidence of considerable hemolysis, the classical findings of CHAD, and an IgM level of 700 mg/100 ml. He was started on chlorambucil in a dose of 2 mg a day in November and his hemoglobin level rose rapidly and the abnormal antibody titre and IgM level gradually fell. Four months later the IgM level was 500 mg/ 100 ml and after another eight months of treatment his IgM level had fallen to within normal limits. Since, at that time, he had a slight lymphopenia and had been feeling extremely well for the past 10 months the Case 4 W S, man aged 57 Chronic CHAD had been diagnosed in December 1964. He was treated initially with blood transfusions and corticosteroid and seemed to have a partial response to this drug. He was first seen by us in July 1966 when he had respiratory symptoms as well as the symptoms and signs of chronic CHAD. His IgM level was 300 mg/100 ml. Duringthecourse ofinvestigations he showed an increased susceptibility to infection and the dose of corticosteroid was reduced rapidly and treatment with chlorambucil, 4 mg a day, was started in August 1966. He showed an immediate response to this drug; the haemoglobin level rose from 12 to 14 g/100 ml, the abnormal antibody titre fell and the level of IgM returned to normal. In November 1966 he was so well that the chlorambucil was reduced to 2 mg a day but one month later he became anxmic again. The dose of chlorambucil was raised to 4 mg a day and the anxmia responded. In February 1967 the dose was again reduced to 2 mg a day and this time he remained well for 4 months.
Then he again relapsed and now failed to respond to chlorambucil in doses of 4 mg or 6 mg daily. He did, however, respond to a 7-day course of intravenous cyclophosphamide. Unfortunately, this drug caused neutropenia and was changed to azathioprine which did not seem to control the disease. While he was receiving azathioprine his hxmoglobin level fell and the antibody titre and the IgM level rose again. A further week's course of intravenous cyclophosphamide seemed to be successful and it was followed by oral cyclophosphamide but this had to be discontinued in December 1967 because of reticulocytopenia.
In January 1968 he was readmitted with a recurrence of his anemia. The pattern of his disease, however, had now changed. The anaemia failed to respond to a further course of cyclophosphamide and The progress of these patients raises several questions. First, are we right to stop the administration of the drug to Case 3 and if not, how long should it be continued? Secondly, in Case 4, should we have been bolder and continued the chlorambucil at the higher dose instead of reducing it? The answers to these questions can only be known by making further observations. The progress of Case 4 demonstrates that the anmmia would respond also to treatment with cyclophosphamide.
These drugs are the first and almost only line of attack in the treatment of CHAD and if the patient is severely handicapped by the disease, do seem to offer some hope of relief. Steroids with or without splenectomy are not usually useful and perhaps should never be used.
Autoimmune Hamolytic Anaemia of the Warm Antibody Type In warm autoimmune hemolytic anxmia (AIHA) the antibody is usually an IgG immunoglobulin often present on the red cells and in the serum only in microgram amounts per 100 ml. It is unusual for the IgG level to be increased above normal. The type of cell forming the antibody has not been established but, presumably by analogy with IgG myeloma, this antibody is produced by plasma cells. Alkylating agents and antimetabolites have, in our hands, played a comparatively small part in the treatment of this disease. Acute hmmolytic episodes are generally controlled with corticosteroids and it is only when long-term I E X . I 1 'f when the patient's anemia has relapsed after splenectomy, that antimetabolites have been tried.
It is difficult to choose a drug for the treatment of this disease. The most useful drugs in the treatment of myelomatosis are melphalan and cyclophosphamide and perhaps these drugs should be used. However, in 1965 Sahair & Schwartz reported that, in rabbits treated with 6-mercaptopurine, inhibition of IgG antibody response could be obtained without affecting the 1gM antibody response.
Because of this and experiments like it 6mercaptopurine and its derivatives have been the most widely used drugs in the treatment of warm AIHA as well as in idiopathic thrombocytopenia and systemic lupus erythematosis. Another factor in the choice of drug has been evidence that azathioprine is a safe and useful drug for sup- Results of treatment with azathioprine: We have treated 6 patients with this drug and Table 2 summarizes the results. In 3 patients the anemia has been controlled and the corticosteroid dose reduced or discontinued. In 2 patients there has been no effect in spite of 9 and 7 months' treatment respectively. In one patient lowering of the corticosteroid dose resulted in worsening of the anemia.
All these patients have been treated with the drug for a maximum of 6 months and the details of the dosage are given in Table 2 . Case 10 (B S), who also had a complex multi-system illness, possibly systemic lupus erythematosis, was treated with azathioprine alternating at monthly intervals with methotrexate. No side-effects have been apparent clinically. Two patients, however, have had profound falls of IgM levels, one of these being also accompanied by a fall in IgA level. No patients have developed leucopenia or thrombocytopenia while on this drug. Fig 3 shows the htmatology chart of Case 11, whose case history is summarized below. Case 11 A H, man aged 58 First diagnosed as having AIHA in 1965. His initial anemia responded well to treatment with corticosteroid but as this drug was reduced his condition relapsed. Again he responded to corticosteroid but he developed a possible duodenal ulcer and severe depression. Since 51Cr-tagged red cell studies had suggested that the spleen was an important organ in red cell destruction the steroids were tailed off and a splenectomy was done. Unfortunately his aneemia recurred after the operation and he was put on azathioprine 100 mg a day. This drug has been continued ever since with a step-wise increase in the dose 21 IN IN 12 a !a 10 In n in until it is now 200 mg a day. On this regime his hiemoglobin level has remained between 12-5 and 13 g/100 ml and his reticulocyte count between 2% and 4 %. The other cellular elements of the blood have been unaffected but there has been a disturbing fall in immunoglobulin levels. The initial figures of 125-100 mg/100 ml for IgA and 200-265 mg/100 ml for IgM have fallen to 32-40 mg and 13-2 mg/100 ml respectively. This has occurred without a really significant fall in IgG level. The amount of antibody on the surface of the red cells as assayed by the direct antiglobulin test has shown no decrease; in fact, the reaction has become stronger.
We may have controlled this patient's anaemia by virtue of the other effects of azathioprine without decreasing the amount of abnormal antibody. The low levels of IgM and IgA may perhaps be due to a combination of splenectomy and the immunosuppressive drug. However, another patient, Case 15, has equally low levels of 1gM without splenectomy. In warm AIHA it may be that trying to lower abnormal antibody titres with azathioprine is too unselective a method of treatment. Other drugs may possibly be more useful.
Some workers, for instance Schwartz &
Dameshek (1962) and Hitzig & Massimo (1966) , have obtained better results with a variety of immunosuppressive drugs, mainly 6-mercaptopurine and its derivatives. Other workers such as Rundles et al. (1961) , Lorenzen & Videback (1965) and Corley et al. (1966) have obtained results comparable with or worse than our own.
Our present policy in the treatment of AIHA of the warm antibody type is to use steroids as the first line of attack. Splenectomy, up till now, has been the second line of attack for those patients who develop complications of steroid therapy and in whom 51Cr-tagged red cell studies have shown that the spleen is a major organ of red cell destruction. Irmmunosuppressive drugs have only been used as a third line of attack. Which is the best drug is uncertain; the results of treatment with azathioprine have been somewhat disappointing. In hemolytic anemias the shortening of red cell life span upsets the balance between production and destruction. Increased destruction resulting from ineffective erythropoiesis (intra-marrow destruction of red cells) increases the severity of the disease; on the other hand, increased red cell production due to marrow expansion tends to compensate for the anemia. In patients with either severe red cell destruction or severe ineffective erythropoiesis compensation is inadequate and serious anmmia results. However, in those patients with only a moderately shortened red cell life span the severity of the anaemia is dependent on the compensation achieved by the marrow. One of the problems is that for a given degree of shortening of red cell life the compensation achieved is variable in spite of the marrow being capable of further expansion. Some clue to the explanation of this paradox can be obtained from the suggestion that the cause of polycythmemia seen in some hemoglobinopathies not associated with hemolysis is their high oxygen affinity. In these patients it has been suggested (Adamson & Stamatoyannopoulos 1967) that since there is less oxygen available to the tissues there is increased erythropoietin production, causing polycytheemia. This concept can be applied to the compensation seen in haemolytic processes due to various abnormal hemoglobins; that is, those abnormal haemoglobins associated with a high oxygen affinity would similarly cause a raised erythropoietin production, and therefore better compensation, for a given shortening of the red cell life than would be seen in those having a normal or decreased oxygen affinity where erythropoietin production would be less stimulated.
To test this hypothesis we studied the oxygen dissociation curve of whole red cells containing a variety of hemoglobins by the following method. Three times washed, fresh red cells were suspended in a phosphate buffer of chosen pH. The suspension was put into a tonometer and deoxygenated using a vacuum and the spectrum recorded using the second sample position of a modified SP 800 recording spectrophotometer (Unicam Instruments Ltd, Cambridge, England). Serial additions I Bilton Pollard Fellow
